ArticleOncology and therapy2020
Gender Differences and Outcomes in Melanoma Patients.
Article in Oncology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 53 citations in OpenAlex.
- Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial.Nature communications · 2024Trial
- Oxidative Stress and Antioxidant Defense Capacity in Patients with Metastatic and Non-Metastatic Cutaneous Melanoma.International journal of molecular sciences · 2026Article
- Design with women in mind.Nature biomedical engineering · 2026Article
- Transdermal Hormonal Therapy in Menopause: Current Evidence and Personalized Approaches.Pharmaceutics · 2026Review
- A novel polymorphism in the TERT gene is associated with lower survival in male patients with melanoma.Molecular medicine (Cambridge, Mass.) · 2026Article
- The role of vitamin C in melanoma cell death via activation of cytochrome C and TNF-α protein expression.Scientific reports · 2025Article
- Role of Androgen Receptor in Melanoma: Mechanisms of Tumor Progression, Immune Evasion, and Therapeutic Implications.Cancers · 2025Review
- Demographic inaccuracies and biases in the depiction of patients by artificial intelligence text-to-image generators.NPJ digital medicine · 2025Article
- Mechanistic insights into proteasome inhibitor MG132 induced apoptosis in melanoma A375 cells.Scientific reports · 2025Article
- Natural Products for Melanoma Therapy: From Traditional Medicine to Modern Drug Discovery.Plants (Basel, Switzerland) · 2025Review
- Pregnancy Complicated by Rapidly Progressing Vulvar Melanoma: A Case Study.The American journal of case reports · 2025Article
- Exploration in association between vitamin D and cutaneous melanoma and explainable machine learning prediction.Frontiers in oncology · 2025Article
- Malignant melanoma with bone metastases in a child: a case report and review of literature.Annals of medicine and surgery (2012) · 2025Article
- Disparities in utilization of novel cancer therapies in advanced stage III and IV melanoma and variance in outcomes.Immunotherapy · 2025Article
- Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study.Cancers · 2024Article
- Review
- Acral Melanoma Incidence and Survival Trends in 1990-2020: A Nationwide, Population-based Study.Acta dermato-venereologica · 2024Article
- Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases-A Danish Real-World Cohort.Cancers · 2024Article
- A Narrative Review of the Role of Estrogen (Receptors) in Melanoma.International journal of molecular sciences · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMelanoma is one of the most common cancers in younger people. The incidence of cutaneous melanoma is increasing in patients of both sexes, with female patients generally living longer than their male counterparts. The aim of this retrospective study was to evaluate and confirm the sex-based difference in survival of melanoma patients and the relationship of this difference with pathological features.
methodsA total of 1023 patients who had been treated at the Department of Medical Oncology, Università Politecnica Marche (Ancona, Italy) and the INRCA-IRCCS Department of Dermatology (Ancona, Italy) between 1987 and 2014 were enrolled in the study.
resultsIn terms of stage of disease at onset, there was a significant difference in disease-free survival (DFS) and overall survival (OS) in favor of female patients in disease stage I (P = 0.001 and P = 0.01, respectively) and II (P = 0.02 and P = 0.009, respectively). Female patients also showed a significant improvement in 12-year DFS and 12-year OS adjusted for pathological features (Breslow thickness, ulceration, "absent" tumor-infiltrating lymphocyte (TIL) melanomas, "non-brisk" TIL pattern). Globally, female patients had an advantage over with male patients in both DFS and OS (P < 0.001).
conclusionsOur results show that women have a survival benefit over with men after adjustment for many variables that can reduce mortality risk in female melanoma patients. In a future investigation we wish to examine possible biological sex differences in tumor-host interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.